Medistim delivers record sales in Q4 2012 with MNOK 49.7 (MNOK 41.3). Strong growth of 13.6% for the full year, reaching MNOK 183.8 (MNOK 161.8). Operating profit (EBIT) for the quarter was MNOK 6.1 (MNOK…Read more
Medistim have received confirmation from Canada Health that the company’s new product VeriQ C is cleared for sale in Canada.Read more
Medistim has signed contracts with three hospitals in the US and achieved its first revenues from the company’s new product VeriQC.
All three hospitals have entered into a lease agreement where they pay per usage. A procedure with VeriQC is priced at about twice the level of a procedure performed using the traditional equipment VeriQ™. The company expects that existing and new customers gradually will convert to VeriQC.Read more
A new transit time flow measurement (TTFM) probe line specifically designed for vascular surgery is being launched at the annual conference of the European Society for Vascular Surgery (ESVS).Read more
MediStim ASA (OSE: MEDI), a Norwegian Medtech company that develops and commercializes medical equipment for use within cardiac and vascular surgery, as well as other surgical fields, announces that the company has entered into a license agreement with Freebit AS.Read more